Rockwell Medical Sets 2029 Targets: $100M+ Sales, 30% Gross Margin, No New Fundraising Needed
RMTI sits 54% above its 52-week low of $4.885.
Summary
Rockwell Medical's investor presentation sets 2029 targets of $100M+ net sales, $5–10M profitability, and ~30% gross margin, and states no additional fundraising is needed for sustained profitability.
Key Events · Earnings and Guidance · RMTI
-
2029 Long-Term Targets Set
By 2029, the company targets net sales above $100 million, profitability of $5–10 million, and gross margin approaching 30%.
-
No Additional Fundraising Required
The presentation states that no additional fundraising is required to achieve sustained profitability, and projects cash flow positive from operations in 2026 and beyond.
-
2026 Guidance Reaffirmed
Reaffirms 2026 guidance: net sales $70–75 million, gross margin 18–22%, adjusted EBITDA $1–2 million.
-
1H'26 Performance
First half 2026 net sales of $35.1 million, gross margin of 17%, and adjusted EBITDA of $(0.4) million.
Analysis · RMTI · Life Sciences
The investor presentation introduces new long-term financial targets through 2029 — net sales above $100 million, profitability of $5–10 million, and gross margin approaching 30% — along with a statement that no additional fundraising is required to reach sustained profitability. These forward-looking commitments go beyond the Q2 results already reported today, providing investors with a concrete multi-year framework for the first time.
At the time of this filing, RMTI was trading at $7.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.6M. The 52-week trading range was $4.89 to $21.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.